How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Aerosolized Anti-Human CD3 Antibodies Decrease Airway Hyperresponsiveness in Non-Human Primates

Organization name

National Jewish Health

Profile

*Method proven in mice

Summary

Researchers at National Jewish Health have discovered that the targeted delivery of anti alpha/beta or gamma/delta T cell monoclonal antibodies can be used as a means to manipulate T cell-dependent regulation of airway reactivity. They have demonstrated that the use of such antibodies can significantly decrease airway hyperreactivity (AHR) in a mouse model of asthma. Therefore, the use of monoclonal antibodies anti-alpha beta or gamma delta T cells could constitute a treatment for asthma and other allergic diseases of the airways.

Potential Applications

Therapy for asthma and chronic obstructive pulmonary disease

Advantages of Invention  

  • Monoclonal antibodies are specific and therefore various subsets of T cell population can be targeted.
  • Low doses of antibody are required.
  • The therapeutical effects of such technique are rapid.
  • The delivery of these antibodies is confined to the airways and does not affect the peripheral immune system.

State of Development

National Jewish Health scientists have demonstrated in a mouse model of asthma that targeted delivery of monoclonal antibodies anti-alpha beta or gamma delta T cells alleviate AHR:

In addition, the same decrease inAHR was demonstrated in mice genetically-deficient in cells targeted by these antibodies. The same scientists have also shown that the cellular effects of these antibodies is localized exclusively to the airways and do not spread systemically .  

Further R&D Required

Applying this technology to other model systems.

Licensing Potential

This technology is available for licensing.

Patent Status

U.S. Patent #8,178,098.

Inventors

  • Willi Born, PhD, Erwin W. Gelfand, MD, Michael Lahn, MD and Arihiko Kanehiro, MD Publications Lahn et al. Int Arch Allergy Immunol. 2004; 134 (1):49-55
  • Lahn et al. Proc. Natl. Acad. Sci. USA, June 25, 2002, 99(13):8850-8855

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries